AU2013356792A1 - Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III - Google Patents
Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III Download PDFInfo
- Publication number
- AU2013356792A1 AU2013356792A1 AU2013356792A AU2013356792A AU2013356792A1 AU 2013356792 A1 AU2013356792 A1 AU 2013356792A1 AU 2013356792 A AU2013356792 A AU 2013356792A AU 2013356792 A AU2013356792 A AU 2013356792A AU 2013356792 A1 AU2013356792 A1 AU 2013356792A1
- Authority
- AU
- Australia
- Prior art keywords
- ppi
- mal
- iii
- dendrimer
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLP.401934 | 2012-12-06 | ||
| PL401934A PL234887B1 (pl) | 2012-12-06 | 2012-12-06 | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
| PCT/PL2013/000154 WO2014088434A1 (en) | 2012-12-06 | 2013-12-03 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013356792A1 true AU2013356792A1 (en) | 2015-07-23 |
Family
ID=49955471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013356792A Abandoned AU2013356792A1 (en) | 2012-12-06 | 2013-12-03 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150320692A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2928478A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016501260A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20150099539A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2013356792A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2896673A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL239143A0 (cg-RX-API-DMAC10.html) |
| PL (1) | PL234887B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014088434A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL234888B1 (pl) * | 2012-12-06 | 2020-04-30 | Univ Lodzki | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208580A1 (en) * | 2005-09-19 | 2009-08-20 | Regents Of The University Of Michigan | Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles |
| US20110177602A1 (en) * | 2007-06-27 | 2011-07-21 | Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG | Composite Structure |
| PL234888B1 (pl) * | 2012-12-06 | 2020-04-30 | Univ Lodzki | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
-
2012
- 2012-12-06 PL PL401934A patent/PL234887B1/pl unknown
-
2013
- 2013-12-03 AU AU2013356792A patent/AU2013356792A1/en not_active Abandoned
- 2013-12-03 KR KR1020157018092A patent/KR20150099539A/ko not_active Withdrawn
- 2013-12-03 WO PCT/PL2013/000154 patent/WO2014088434A1/en not_active Ceased
- 2013-12-03 US US14/650,458 patent/US20150320692A1/en not_active Abandoned
- 2013-12-03 EP EP13821003.4A patent/EP2928478A1/en not_active Withdrawn
- 2013-12-03 CA CA2896673A patent/CA2896673A1/en not_active Abandoned
- 2013-12-03 JP JP2015546418A patent/JP2016501260A/ja active Pending
-
2015
- 2015-06-02 IL IL239143A patent/IL239143A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016501260A (ja) | 2016-01-18 |
| PL234887B1 (pl) | 2020-04-30 |
| EP2928478A1 (en) | 2015-10-14 |
| US20150320692A1 (en) | 2015-11-12 |
| KR20150099539A (ko) | 2015-08-31 |
| IL239143A0 (en) | 2015-07-30 |
| CA2896673A1 (en) | 2014-06-12 |
| PL401934A1 (pl) | 2014-06-09 |
| WO2014088434A1 (en) | 2014-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feng et al. | Mitochondria-associated ER stress evokes immunogenic cell death through the ROS-PERK-eIF2α pathway under PTT/CDT combined therapy | |
| Zhao et al. | Sonodynamic therapy of NRP2 monoclonal antibody‐guided MOFs@ COF targeted disruption of mitochondrial and endoplasmic reticulum homeostasis to induce autophagy‐dependent ferroptosis | |
| Xu et al. | Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance | |
| Liu et al. | Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-κB pathways | |
| Hsin et al. | The apoptotic effect of nanosilver is mediated by a ROS-and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells | |
| Zhang et al. | Prussian blue/calcium peroxide nanocomposites-mediated tumor cell iron mineralization for treatment of experimental lung adenocarcinoma | |
| Sun et al. | Multi‐enzyme activity of MIL‐101 (Fe)‐derived cascade nano‐enzymes for antitumor and antimicrobial therapy | |
| Zanotto-Filho et al. | The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma | |
| Ziemba et al. | Toxicity and proapoptotic activity of poly (propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer | |
| Ahir et al. | Tailored-CuO-nanowire decorated with folic acid mediated coupling of the mitochondrial-ROS generation and miR425-PTEN axis in furnishing potent anti-cancer activity in human triple negative breast carcinoma cells | |
| US9861659B2 (en) | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof | |
| Yusuf et al. | Liposomal encapsulation of silver nanoparticles (AgNP) improved nanoparticle uptake and induced redox imbalance to activate caspase-dependent apoptosis | |
| Mameri et al. | Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane | |
| Zhang et al. | α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer | |
| Ponraj et al. | Mitochondrial dysfunction-induced apoptosis in breast carcinoma cells through a pH-dependent intracellular quercetin NDDS of PVPylated-TiO2NPs | |
| Albuz et al. | Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results | |
| Su et al. | Roles of PTEN gene methylation in Se-CQDs induced mitochondrial apoptosis of osteosarcoma cells | |
| Wang et al. | Endoplasmic reticulum-mitochondria dual-targeting nanoplatform suppresses cancer stemness and enhances colorectal cancer immunotherapy | |
| US9877985B2 (en) | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III | |
| Murera et al. | Few layer graphene does not affect the function and the autophagic activity of primary lymphocytes | |
| US20150320692A1 (en) | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii | |
| Jiang et al. | Iterative‐Designed Multifunctional Carbon Dots Nanodrug for Celastrol Loading, Targeting Delivery, and Combination Therapy of Kidney Stones | |
| US10022395B2 (en) | Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III | |
| JP2004534001A (ja) | 細胞に化学化合物を標的化する方法およびそれに使用する製薬学的組成物 | |
| Wibowo et al. | Effect of degree of acidity and solvent on structural analysis of 1-(2, 5-dihydroxyphenyl)-3-pyridine-2-yl-propenone and cytotoxic activity on T47D cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |